Prognostic value of preoperative positron emission tomography in resected stage I non-small cell lung cancer

Boone Goodgame, Giancarlo A. Pillot, Zhiyun Yang, Jabi Shriki, Bryan F. Meyers, Jennifer Zoole, Feng Gao, Farrokh Dehdashti, Alexander Patterson, Barry A. Siegel, Ramaswamy Govindan

Research output: Contribution to journalArticle

79 Citations (Scopus)

Abstract

PURPOSE: Approximately 20 to 40% of patients with surgically resected stage I non-small cell lung cancer (NSCLC) will develop recurrent disease. Positron emission tomography (PET) with 2-[F] fluoro-2-deoxy-D-glucose (FDG) is used often in staging NSCLC. We conducted this study to determine whether the preoperative maximum tumor standardized uptake value (SUVmax) was associated with recurrence in patients with resected stage I NSCLC. PATIENTS AND METHODS: We identified consecutive patients who underwent curative surgical resection for stage I NSCLC between 1999 and 2003 who had preoperative FDG-PET imaging. Patients were divided into two cohorts based on SUVmax above or below the median for the group. Recurrence rates were estimated by the Kaplan-Meier method and overall survival was analyzed as a secondary end point. RESULTS: Of 136 patients who met inclusion criteria, 77 (57%) had T1 and 59 (43%) had T2 tumors. The median follow-up time was 46 months and 32 patients had a disease recurrence. The median SUVmax was 5.5. The 5-year estimates of recurrence rates for patients with low and high SUVmax were 14% and 37%, respectively (p = 0.002), with 5-year overall survivals of 74% and 53%, respectively (p = 0.006). In multivariate analyses based on SUVmax, T-classification, age, and histology, high SUVmax was independently associated with recurrence (p = 0.002) and mortality (p = 0.041). CONCLUSION: High SUVmax (≥5.5) on preoperative FDG-PET is an independent predictor of relapse and death in resected stage I NSCLC. Prospective trials of adjuvant chemotherapy in patients with stage I NSCLC and high SUVmax should be considered.

Original languageEnglish (US)
Pages (from-to)130-134
Number of pages5
JournalJournal of Thoracic Oncology
Volume3
Issue number2
DOIs
StatePublished - Feb 2008

Fingerprint

Non-Small Cell Lung Carcinoma
Positron-Emission Tomography
Recurrence
Deoxyglucose
Survival
Fluorodeoxyglucose F18
Adjuvant Chemotherapy
Neoplasms
Histology
Multivariate Analysis
Mortality

Keywords

  • Early stage
  • Imaging
  • Non-small cell lung cancer
  • PET
  • Prognosis
  • Stage I
  • Surgery outcomes

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

Goodgame, B., Pillot, G. A., Yang, Z., Shriki, J., Meyers, B. F., Zoole, J., ... Govindan, R. (2008). Prognostic value of preoperative positron emission tomography in resected stage I non-small cell lung cancer. Journal of Thoracic Oncology, 3(2), 130-134. https://doi.org/10.1097/JTO.0b013e318160c122

Prognostic value of preoperative positron emission tomography in resected stage I non-small cell lung cancer. / Goodgame, Boone; Pillot, Giancarlo A.; Yang, Zhiyun; Shriki, Jabi; Meyers, Bryan F.; Zoole, Jennifer; Gao, Feng; Dehdashti, Farrokh; Patterson, Alexander; Siegel, Barry A.; Govindan, Ramaswamy.

In: Journal of Thoracic Oncology, Vol. 3, No. 2, 02.2008, p. 130-134.

Research output: Contribution to journalArticle

Goodgame, B, Pillot, GA, Yang, Z, Shriki, J, Meyers, BF, Zoole, J, Gao, F, Dehdashti, F, Patterson, A, Siegel, BA & Govindan, R 2008, 'Prognostic value of preoperative positron emission tomography in resected stage I non-small cell lung cancer', Journal of Thoracic Oncology, vol. 3, no. 2, pp. 130-134. https://doi.org/10.1097/JTO.0b013e318160c122
Goodgame, Boone ; Pillot, Giancarlo A. ; Yang, Zhiyun ; Shriki, Jabi ; Meyers, Bryan F. ; Zoole, Jennifer ; Gao, Feng ; Dehdashti, Farrokh ; Patterson, Alexander ; Siegel, Barry A. ; Govindan, Ramaswamy. / Prognostic value of preoperative positron emission tomography in resected stage I non-small cell lung cancer. In: Journal of Thoracic Oncology. 2008 ; Vol. 3, No. 2. pp. 130-134.
@article{bb861a96556d4fbd89a448b5253ceb2e,
title = "Prognostic value of preoperative positron emission tomography in resected stage I non-small cell lung cancer",
abstract = "PURPOSE: Approximately 20 to 40{\%} of patients with surgically resected stage I non-small cell lung cancer (NSCLC) will develop recurrent disease. Positron emission tomography (PET) with 2-[F] fluoro-2-deoxy-D-glucose (FDG) is used often in staging NSCLC. We conducted this study to determine whether the preoperative maximum tumor standardized uptake value (SUVmax) was associated with recurrence in patients with resected stage I NSCLC. PATIENTS AND METHODS: We identified consecutive patients who underwent curative surgical resection for stage I NSCLC between 1999 and 2003 who had preoperative FDG-PET imaging. Patients were divided into two cohorts based on SUVmax above or below the median for the group. Recurrence rates were estimated by the Kaplan-Meier method and overall survival was analyzed as a secondary end point. RESULTS: Of 136 patients who met inclusion criteria, 77 (57{\%}) had T1 and 59 (43{\%}) had T2 tumors. The median follow-up time was 46 months and 32 patients had a disease recurrence. The median SUVmax was 5.5. The 5-year estimates of recurrence rates for patients with low and high SUVmax were 14{\%} and 37{\%}, respectively (p = 0.002), with 5-year overall survivals of 74{\%} and 53{\%}, respectively (p = 0.006). In multivariate analyses based on SUVmax, T-classification, age, and histology, high SUVmax was independently associated with recurrence (p = 0.002) and mortality (p = 0.041). CONCLUSION: High SUVmax (≥5.5) on preoperative FDG-PET is an independent predictor of relapse and death in resected stage I NSCLC. Prospective trials of adjuvant chemotherapy in patients with stage I NSCLC and high SUVmax should be considered.",
keywords = "Early stage, Imaging, Non-small cell lung cancer, PET, Prognosis, Stage I, Surgery outcomes",
author = "Boone Goodgame and Pillot, {Giancarlo A.} and Zhiyun Yang and Jabi Shriki and Meyers, {Bryan F.} and Jennifer Zoole and Feng Gao and Farrokh Dehdashti and Alexander Patterson and Siegel, {Barry A.} and Ramaswamy Govindan",
year = "2008",
month = "2",
doi = "10.1097/JTO.0b013e318160c122",
language = "English (US)",
volume = "3",
pages = "130--134",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",
number = "2",

}

TY - JOUR

T1 - Prognostic value of preoperative positron emission tomography in resected stage I non-small cell lung cancer

AU - Goodgame, Boone

AU - Pillot, Giancarlo A.

AU - Yang, Zhiyun

AU - Shriki, Jabi

AU - Meyers, Bryan F.

AU - Zoole, Jennifer

AU - Gao, Feng

AU - Dehdashti, Farrokh

AU - Patterson, Alexander

AU - Siegel, Barry A.

AU - Govindan, Ramaswamy

PY - 2008/2

Y1 - 2008/2

N2 - PURPOSE: Approximately 20 to 40% of patients with surgically resected stage I non-small cell lung cancer (NSCLC) will develop recurrent disease. Positron emission tomography (PET) with 2-[F] fluoro-2-deoxy-D-glucose (FDG) is used often in staging NSCLC. We conducted this study to determine whether the preoperative maximum tumor standardized uptake value (SUVmax) was associated with recurrence in patients with resected stage I NSCLC. PATIENTS AND METHODS: We identified consecutive patients who underwent curative surgical resection for stage I NSCLC between 1999 and 2003 who had preoperative FDG-PET imaging. Patients were divided into two cohorts based on SUVmax above or below the median for the group. Recurrence rates were estimated by the Kaplan-Meier method and overall survival was analyzed as a secondary end point. RESULTS: Of 136 patients who met inclusion criteria, 77 (57%) had T1 and 59 (43%) had T2 tumors. The median follow-up time was 46 months and 32 patients had a disease recurrence. The median SUVmax was 5.5. The 5-year estimates of recurrence rates for patients with low and high SUVmax were 14% and 37%, respectively (p = 0.002), with 5-year overall survivals of 74% and 53%, respectively (p = 0.006). In multivariate analyses based on SUVmax, T-classification, age, and histology, high SUVmax was independently associated with recurrence (p = 0.002) and mortality (p = 0.041). CONCLUSION: High SUVmax (≥5.5) on preoperative FDG-PET is an independent predictor of relapse and death in resected stage I NSCLC. Prospective trials of adjuvant chemotherapy in patients with stage I NSCLC and high SUVmax should be considered.

AB - PURPOSE: Approximately 20 to 40% of patients with surgically resected stage I non-small cell lung cancer (NSCLC) will develop recurrent disease. Positron emission tomography (PET) with 2-[F] fluoro-2-deoxy-D-glucose (FDG) is used often in staging NSCLC. We conducted this study to determine whether the preoperative maximum tumor standardized uptake value (SUVmax) was associated with recurrence in patients with resected stage I NSCLC. PATIENTS AND METHODS: We identified consecutive patients who underwent curative surgical resection for stage I NSCLC between 1999 and 2003 who had preoperative FDG-PET imaging. Patients were divided into two cohorts based on SUVmax above or below the median for the group. Recurrence rates were estimated by the Kaplan-Meier method and overall survival was analyzed as a secondary end point. RESULTS: Of 136 patients who met inclusion criteria, 77 (57%) had T1 and 59 (43%) had T2 tumors. The median follow-up time was 46 months and 32 patients had a disease recurrence. The median SUVmax was 5.5. The 5-year estimates of recurrence rates for patients with low and high SUVmax were 14% and 37%, respectively (p = 0.002), with 5-year overall survivals of 74% and 53%, respectively (p = 0.006). In multivariate analyses based on SUVmax, T-classification, age, and histology, high SUVmax was independently associated with recurrence (p = 0.002) and mortality (p = 0.041). CONCLUSION: High SUVmax (≥5.5) on preoperative FDG-PET is an independent predictor of relapse and death in resected stage I NSCLC. Prospective trials of adjuvant chemotherapy in patients with stage I NSCLC and high SUVmax should be considered.

KW - Early stage

KW - Imaging

KW - Non-small cell lung cancer

KW - PET

KW - Prognosis

KW - Stage I

KW - Surgery outcomes

UR - http://www.scopus.com/inward/record.url?scp=40049084958&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40049084958&partnerID=8YFLogxK

U2 - 10.1097/JTO.0b013e318160c122

DO - 10.1097/JTO.0b013e318160c122

M3 - Article

C2 - 18303432

AN - SCOPUS:40049084958

VL - 3

SP - 130

EP - 134

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 2

ER -